In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment

International Journal of Cancer

Volumn 65, Issue 1, 1996, Pages 80-84

  Teicher, Beverly A ^a   Ara, Gulshan ^a   Menon, Krishna ^a   Schaub, Robert G ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT COLONY STIMULATING FACTOR 1; RECOMBINANT INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY CARCINOMA; LEWIS CARCINOMA; MALE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; INTERLEUKIN-12; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0030028620     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960103)65:1<80::AID-IJC14>3.0.CO;2-M     Document Type: Article

References (28)

1. BONTA, I.L. and BEN-EFRAIM, S., Involvement of inflammatory mediators in macrophage antitumor activity. J. Leukocyte Biol., 54, 613-626 (1993).
2. BRUNDA, M.J., Interleukin-12. J. Leukocyte Biol., 55, 280-288 (1994).
3. BRUNDA, M.J., LUISTRO, L., WARRIER, R.R., WRIGHT, R.B., HUBBARD, B.R., MURPHY, M., WOLF, S.F. and GATELY, M.K., Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. exp. Med., 178, 1223-1230 (1993).
4. CHAN, S.H., PERUSSIA, B., GUPTA, J.W., KOBAYASHI, M., POSPISIL, M., YOUNG, H.A., WOLF, S.F., YOUNG, D., CLARK, S.C. and TRINCHIERI, G., Induction of Interferon γ production by natural killer cell stimulatory factor: characterization of the responding cells and synergy with other inducers. J. exp. Med., 173, 869-879 (1991).
5. COLE, D.J., and 15 OTHERS, Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer. J. nat. Cancer Inst., 86, 39-45 (1994).
6. ETO, T., TAKAMATSU, Y., HARADA, M., HARADA, N., AKASHI, K., TESHIMA, T., INABA, S., OKAMURA, T. and NIHO, Y., Effects of macrophage colony-stimulating factor (M-CSF) on the mobilization of peripheral blood stem cells. Bone Marrow Transpl., 13, 125-129 (1994).
7. GATELY, M.K., DESAI, B., WOLITZKY, A.G., QUINN, P.M., DWYER, C.M., PODLASKI, F.J., FAMILLETTI, P.C., SINIGAGLIA, F., CHIZZONITE, L R., GUBLER, U. and STERN, A.S., Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol., 147, 874-882 (1991).
8. GATELY, M.K., WARRIER, R.R., HONASOGE, S., CARVAJAL, D.M., FAHERTY, D.A., CONNAUGHTON, S.E., ANDERSON, T.D., SARMIENTO, U., HUBBARD, B.R., and MURPHY, M., Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int. Immunol., 6, 157-167 (1994).
9. GATELY, M.K., WOLITZKY, A.G., QUINN, P.M. and CHIZZONITE, R., Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell. Immunol., 143, 127-142 (1992).
10. GAZZINELLI, R.T., HIENY, S., WYNN, T.A., WOLF, S. and SHER, A., Interleukin 12 is required for the T-lymphocyte-independent induction of interferon γ by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc. nat. Acad. Sci. (Wash.). 90, 6115-6119 (1993).
11. KEDAR, E. and KLEIN, E., Cancer immunotherapy: are the results discouraging? Can they be improved? Adv. Cancer Res., 59, 245-322 (1992).
12. LOCKSLEY, R.M., Interleukin 12 in host defense against microbial pathogens. Proc. nat. Acad. Sci. (Wash.), 90, 5879-5880 (1993).
13. LU, L., SHEN, R.-N., LIN, Z.-H., AUKERMAN, S.L., RALPH, P. and BROXMEYER, H.E., Anti-tumor effects of recombinant human macrophage colony-stimulating factor, alone or in combination with local irradiation, in mice inoculated with Lewis lung carcinoma cells. Int. J. Cancer, 47, 143-147 (1991).
14. MOTOYOSHI, K., Macrophage colony-stimulating factor for cancer therapy. Oncology, 51, 198-204 (1994).
15. MUNN, D.H. and CHEUNG, N.K., Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor: induction of efficient antibody mediated antitumor cytotoxicity not detected by isotope release assays. J. exp. Med., 170, 511-526 (1989).
16. NASTALA, C.L., EDINGTON, H.D., MCKINNEY, T.G., TAHARA, H., NALESNIK, M.A., BRUNDA, M.J., GATELY, M.K., WOLF, S.F., SCHREIBER, R.D., STORKUS, W.J. and LOTZE. M.T., Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol., 153, 1697-1706 (1994).
17. + NK cells. J. Immunol., 148, 2429-2436 (1992).
18. NOGUCHI, Y., RICHARDS, E.C., CHEN, Y.-T. and OLD, L.J., Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. nat. Acad. Sci. (Wash.), 92, 2219-2223 (1995).
19. + T lymphocytes, and NK cells. J. Immunol., 149, 3495-3502 (1992).
20. ROBERTSON, M.J., SOIFFER, R.J., WOLF, S.F., MANLEY, T.J., DONAHUE, C., YOUNG, D., HERRMANN, S.H. and RITZ, J., Responses of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. exp. Med., 175, 779-788 (1992).
21. SANDA, M.G., YANG, J.C., TOPALIAN, S.L., GROVES, E.S., CHILDS, A., BELFORT, JR., R., DE SMET, M.D., SCHWARTZENTRUBER, D.J., WHITE, D.E., LOTZE, M.T. and ROSENBERG, S.A., Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study. J. clin. Oncol., 10, 1643-1649 (1992).
22. + T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming. Proc. nat. Acad. Sci. (Wash.), 90, 10188-10192 (1993).
23. TANG, R., BEUVON, F., OJEDA, M., MOSSERI, V., POUILLART, P. and SCHOOL, S., M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes? Cell. Biochem., 50, 350-356 (1992).
24. TEICHER, B.A., HERMAN, T.S., HOLDEN, S.A. and EDER, J.P., Chemotherapeutic potentiation through interaction at the level of DNA. In: T.-C. Chow and D.C. Rideout (eds.), Synergism and antagonism in chemotherapy, pp. 541-584, Academic Press, New York (1991).
25. VANDEPOL, C.J. and GARNICK, M.B., Clinical applications of recombinant macrophage-colony stimulating factor (rhM-CSF). Biotechnol. Ther., 2, 231-239 (1991).
26. WOLF, S.F., SIEBURTH, D. and SYPEK, J., Interleukin 12: a key modulator of immune function. Stem Cells, 12, 154-168 (1994).
27. YOSHIDA, A., KOIDE, Y., UCHIJIMA, M. and YOSHIDA, T.O., IFN-γ induces IL-12 mRNA expression by a murine macrophage cell line, J774. Biochem. Biophys. Res. Comm., 198, 857-861 (1994).
28. ZEH III, H.J., HURD, S., STORKUS, W.J. and LOTZE, M.T., Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J. Immunother., 14, 155-161 (1993).